Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer

(2010) Kokichi Sugano et al.   CANCER SCIENCE

Personalized medicine: a personal view

(2010) S.A. Narod   Current Oncology

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer

(2009) Ava Kwong et al.   BREAST CANCER RESEARCH AND TREATMENT

BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer

(2009) Michael J. Hall et al.   CANCER

Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country

(2009) Cheng-Har Yip et al.   WORLD JOURNAL OF SURGERY

BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer

(2008) Weiqiu Chen et al.   BREAST CANCER RESEARCH AND TREATMENT

Variation of Breast Cancer Risk Among BRCA1/2 Carriers

(2008) Colin B. Begg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Performance ofBRCA1/2Mutation Prediction Models in Asian Americans

(2008) Allison W. Kurian et al.   JOURNAL OF CLINICAL ONCOLOGY